Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOMe_aFers_1: Ferric Carboxymaltose vs Iron Isomaltoside 1000 in Iron-Deficiency Anemia
NCT02905539Phase 4Completed
- Sponsor
- Saarland University
- Start
- Jul 2016
- Primary completion
- Jun 2020
- Modality
- Inorganic Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of ferric derisomaltose in iron deficiency anemia (IDA) (2 arms), sponsored by Saarland University. Primary endpoint: Incidence of hypophosphatemia at Day 35. Started Jul 2016; status: completed.
02
Drugs
ferric derisomaltose
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT02905539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02905539.